Literature DB >> 1901393

Endocrine control of hypothalamic and pituitary met-enkephalin and beta-endorphin contents.

F Tang1.   

Abstract

This review summarizes the recent findings on the effects of endocrine manipulation on the hypothalamic and pituitary contents of met-enkephalin and beta-endorphin. In the pituitary, gonadectomy decreases beta-endorphin content in both the anterior lobe and neuro-intermediate lobe. Orchidectomy results in a decrease while ovariectomy leads to an increase in anterior lobe met-enkephalin contents. Adrenalectomy only lead to an increase in beta-endorphin contents in the anterior pituitary lobe. Hypothyroidism induced by propylthiouracil treatment is accompanied by a decrease of beta-endorphin in the neuro-intermediate lobe and a decrease in met-enkephalin in the anterior lobe while thyroidectomy entails a decrease in met-enkephalin in the anterior lobe only. Chemically induced diabetes mellitus results in a decrease in beta-endorphin content in the hypothalamus and the neuro-intermediate lobe, and a reduction in met-enkephalin level in the anterior and neuro-intermediate lobes. All these changes are reversible with appropriate hormone treatments. These results indicate the importance of hormones in the regulation of the synthesis and/or release of the opioid peptides in the hypothalamus and the pituitary.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901393     DOI: 10.1159/000125798

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  2 in total

1.  Androgens block outward potassium currents and decrease spontaneous action potentials in GH3 cells.

Authors:  Lorena Suárez; Usama Bilal; Javier Bordallo; Begoña Cantabrana; Manuel Sánchez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-26       Impact factor: 3.000

Review 2.  Acupoint-specific, frequency-dependent, and improved insulin sensitivity hypoglycemic effect of electroacupuncture applied to drug-combined therapy studied by a randomized control clinical trial.

Authors:  Rong-Tsung Lin; Chung-Yuh Tzeng; Yu-Chen Lee; Ying-I Chen; Tai-Hao Hsu; Jaung-Geng Lin; Shih-Liang Chang
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-16       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.